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9ABSTRACT
An imbalance between free radical production and antioxidant defence may contribute to
atherogenesis. Prospective studies suggest that high intake of antioxidant vitamins – dietary or
supplemental – may be protective against cardiovascular diseases.
The present work examined, first, the relation between classical atherosclerotic risk factors and diet and
risk for two manifestations of peripheral atherosclerosis, i.e., intermittent claudication and abdominal
aortic aneurysm; second, the effect of alpha-tocopherol and beta-carotene supplementation on the risk
for the two endpoints; third, the effect of supplementation on the progression of claudication.
The present work is part of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study,
which was a randomized, double-blind, placebo-controlled trial primarily undertaken to examine the
effect of alpha-tocopherol and beta-carotene supplementation on the development of lung cancer and
secondary on the development of other cancers and cardiovascular diseases. Participants were 50- to
69-year-old male smokers living in southwestern Finland (n = 29 133). They were randomly assigned
to receive either 50 mg of alpha-tocopherol, 20 mg of beta-carotene, or both, or placebo daily in a 2 x 2
factorial design. At study entry (1985-1988) several risk factors were assessed covering medical
history, diet, serum lipids, and blood pressure. The follow-up (ending in spring 1993) consisted of
regular follow-up visits and monitoring of national morbidity and mortality registers.
Intermittent claudication was evaluated through a structured questionnaire (Rose) at baseline and
annually thereafter. Among the 26 872 subjects without intermittent claudication at study entry, 2 578
new cases with typical intermittent claudication were detected during a mean follow-up of 4 years.
Serum total cholesterol, blood pressure, age, smoking, and history of diabetes were positively
associated with risk for intermittent claudication, whereas HDL-cholesterol, moderate exercise, and
basic education were inversely associated with the risk. Smoking cessation during follow-up reduced
significantly the subsequent risk for claudication. Additionally, high intake of energy, carbohydrate,
fiber, n-6 polyunsaturated fatty acids, vitamin C, gamma-tocopherol, and carotenoids was associated
with decreased risk for intermittent claudication compared to low intake.
Among subjects free of intermittent claudication at study entry (n = 26 872), no beneficial effect on
claudication incidence was observed with alpha-tocopherol supplementation compared to those not
supplemented with alpha-tocopherol. Correspondingly, supplementation with beta-carotene showed no
effect. Neither was there any effect of either supplementation on the recurrence of claudication among
those 1 484 subjects who had intermittent claudication at study entry. Among the same symptomatic
subjects, risk for peripheral arterial surgery was significantly increased with beta-carotene
supplementation, but alpha-tocopherol supplementation showed no effect.
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Abdominal aortic aneurysm cases were detected through registers, and the diagnoses were checked.
Among the 29 133 ATBC Study subjects, 181 experienced rupture of an abdominal aortic aneurysm or
underwent surgery with graft placement due to a large abdominal aortic aneurysm. Serum total
cholesterol, blood pressure, age, and years of smoking were observed to be independent risk factors for
large abdominal aortic aneurysm, whereas high HDL-cholesterol level was associated with decreased
risk. No associations between nutrient intakes and risk for aortic aneurysm were observed.
Supplementation with alpha-tocopherol compared to no alpha-tocopherol, or with beta-carotene
compared to no beta-carotene showed no effect on the risk for large abdominal aortic aneurysm during
a mean follow-up of 5.8 years.
In conclusion, classical risk factors for coronary heart disease seem to be independent risk factors both
for intermittent claudication and for abdominal aortic aneurysm. A diet rich in vegetables, fruits, and
vegetable oils may be protective against intermittent claudication among older male smokers. Smoking
cessation seems to be effective in prevention of intermittent claudication. No evidence supports
supplemental use of alpha-tocopherol or beta-carotene in order to prevent intermittent claudication or
abdominal aortic aneurysm, nor for treatment of intermittent claudication among life-long male
smokers.
1. INTRODUCTION
Atherosclerotic diseases are the major causes of morbidity and mortality in developed countries.
Manifestations can be chronic, decreasing quality of life, or acute, causing sudden and often premature
death or severe disablement. Thus, the burden of atherosclerotic diseases is considerable upon both
diseased individuals and the whole of society. A huge amount of research has been focused on
developing new drugs and treatment procedures, and solving the pathophysiology of atherosclerosis.
Today, atherosclerosis is more than just accumulation of lipids: it is considered an inflammatory-
related disease (Ross, 1999; Berliner et al., 1995).
Epidemiologic studies have revealed many risk factors for atherosclerosis, most of them dependent on
our lifestyle or on our genome. Additionally, protective factors have been suggested, among them
antioxidants. A diet rich in vegetables and fruits has been associated with lower risk for coronary heart
disease. Similar associations have been reported for high intake of antioxidant vitamins and fiber, and
for high serum levels of vitamins E and C, and carotenoids.
The link between antioxidant vitamins and atherosclerosis is the oxidation hypothesis. One key step in
the atherogenic cascade is the oxidative modification of low-density lipoprotein (LDL) in the vessel
wall. Oxidized LDL enhances inflammatory and thrombotic processes involved in atherogenesis
(Kaplan and Aviram, 1999). It is taken up by macrophages through the scavenger receptor system,
which lacks a feedback mechanism. The uncontrolled accumulation of lipids into the macrophages
leads to the foam cell formation and eventually to fatty streaks. Lipoproteins carry antioxidants, most
abundantly alpha-tocopherol (main constituent of vitamin E) and beta-carotene. During oxidative
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conditions antioxidants are suggested to protect polyunsaturated fatty acids from oxidation. Alpha-
tocopherol is considered the most efficient chain-breaking antioxidant, whereas beta-carotene acts as a
singlet-oxygen quencher. In-vitro studies have consistently shown that alpha-tocopherol increases
resistance of LDL to copper-induced oxidation (Princen et al., 1995; Dieber-Rotheneder et al., 1991),
whereas data on beta-carotene is less consistent (Reaven et al., 1994; Levy et al., 1996). Although
experimental studies indicate that natural antioxidants may reduce oxidative processes involved in
atherogenesis, clinical trials conducted thus far have not confirmed beneficial effects of antioxidant
supplementation on cardiovascular events (Virtamo et al., 1998; Hennekens et al., 1996).
In the clinical trials most attention has been paid to myocardial infarction or to cardiovascular
mortality, with less interest focused on peripheral atherosclerosis. Atherosclerosis in pelvic or femoral
arteries leads to intermittent claudication – exercise-induced pain in calves – which limits everyday
activities. If blood flow is sufficiently impaired, vascular surgery is required. Atherosclerotic changes
in the aorta may lead to aneurysm formation. Large abdominal aortic aneurysms are often
asymptomatic until a life-threatening event of rupture.
The beneficial effect of vitamin E on intermittent claudication was suggested as early as in 1948 (Shute
et al., 1948), although at that time, the antioxidant properties of vitamin E were unknown. During the
next decades, a few small controlled studies were performed, some supporting the early clinical
findings and some indicating no effect. However, an implication of possible beneficial effect remained,
and use of vitamin E supplementation has been recommended to many patients suffering from
intermittent claudication.
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study was designed not only to
explore effects of alpha-tocopherol and beta-carotene supplementation on cancer incidence but also on
cardiovascular diseases. The design’s being randomized, double-blind, placebo-controlled trial, and the
large number of participants offered a good opportunity to find answers to questions such as: whether
antioxidant supplementation has any effect on incidence of intermittent claudication or abdominal
aortic aneurysm, or whether it relieves claudication. Additionally, the ATBC Study design included
measurements of many cardiovascular risk factors and an extensive dietary assessment. Hence the
ATBC Study was suitable also for cohort analysis, and it was possible to obtain new information on
life-style factors associated with risk for intermittent claudication and abdominal aortic aneurysms.
2. REVIEW OF THE LITERATURE
2.1 The oxidation hypothesis
Reactive oxygen species are continuously generated in the body both as a consequence of normal
cellular respiration and by exogenous oxidants (Maxwell, 1995). Several lines of defense against these
free radicals exist. These comprise endogenous enzymes (catalase, glutathione peroxidase, and
superoxide dismutase), non-enzymatic endogenous compounds (urate, bilirubine, glutathione, and
coenzyme Q) and antioxidant vitamins (beta-carotene, vitamin E, and C). Normally, the generation and
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elimination of free radicals is in balance. It is suggested that oxidative damage is involved in the
pathogenesis of many diseases, including atherogenesis, cancer, arthritis, and cataracts as well as in
aging. Thus, it has been hypothesized that if endogenous antioxidant mechanisms are inadequate, a
greater amount of diet-derived antioxidants may prove beneficial in prevention of degenerative
diseases.
One major risk factor for atherosclerotic vascular disease is elevated levels of low-density lipoprotein
(LDL). The earliest sign of atherosclerosis is fatty-streak formation. Fatty streaks contain foam cells,
i.e., macrophages loaded with cholesterol. It has been shown that macrophages take up modified LDL
but not native LDL by a scavenger receptor pathway which is not downregulated (Esterbauer et al.,
1989). In-vitro studies indicate that the arterial wall cells: endothelial cells, smooth muscle cells,
monocyte-macrophages, and neutrophils are able to oxidatively modify LDL (Gokce and Frei, 1996).
Modification of LDL in the subendothelial space is suggested to occur in steps leading first in
minimally oxidized LDL. Further oxidation leads to alterations in apolipoprotein B, which is needed
before oxidized LDL is recognized by the macrophage scavenger receptor (Gokce and Frei, 1996).
However, the latest evidence indicates that oxidative changes do not occur in apolipoprotein B, rather
oxidized lipids are attached to it, leading to recognition by a scavenger receptor (Parthasarathy et al.,
1999; Bird et al., 1999). Oxidized LDL has several atherogenic properties. LDL induces recruitment of
monocytes by stimulating endothelial cells, which also liberate cytokines that are chemotactic for T-
lymphocytes and neutrophils. It stimulates differentiation of monocytes into macrophages.
Furthermore, oxidized LDL induces proliferation of smooth muscle cells, impairs endothelial function,
and it is cytotoxic, inducing prothrombotic factors and stimulation of matrix-degrading enzymes
(Kaplan and Aviram, 1999).
2.2 LDL and antioxidants
Lipoproteins transport cholesterol between the liver and tissues. They also carry lipid-soluble
antioxidants: alpha-tocopherol, gamma-tocopherol, coenzyme-Q, beta-carotene, and other carotenoids.
The antioxidants are suggested to protect the polyunsaturated fatty acids in LDL from peroxidation.
Esterbauer and his co-workers demonstrated that, under Cu++ -stimulated oxidation, antioxidants are
consumed in the sequence: tocopherols first and beta-carotene last before peroxidation occurs
(Esterbauer et al., 1989). Several studies have shown that alpha-tocopherol supplementation increases
resistance of LDL to oxidation (Princen et al., 1995; Jialal et al., 1995; Dieber-Rotheneder et al., 1991).
Although supplementation with high-doses of beta-carotene increases its content in LDL, susceptibility
of LDL to oxidation has not been consistently reduced (Princen et al., 1992; Reaven et al., 1994;
Gaziano et al., 1995; Levy et al., 1996). Beta-carotene is suggested to act in the vessel wall, inhibiting
LDL oxidation induced by intimal cells (Reaven et al., 1994; Dugas et al., 1999). One should bear in
mind that the in-vitro studies of LDL oxidation and antioxidant protection may not reflect actual
conditions in the arterial wall. There is evidence indicating the presence of oxidized LDL in vivo. LDL
extracted from human atherosclerotic lesions has shown great resemblance to in-vitro oxidized LDL
indicating, that atheromas in vivo contain oxidatively modified LDL (Ylä-Herttuala et al., 1989).
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Additionally, auto-antibodies against oxidized LDL have been found in human serum (Palinski et al.,
1988; Salonen et al., 1992), and titers were higher among patients with carotid atherosclerosis than
among controls (Salonen et al., 1992).
2.3 Biology, sources, and function of antioxidant vitamins
Vitamin E
Vitamin E is a lipid-soluble vitamin present in cell membranes and lipoproteins. Vitamin E is a
collective name for four different tocopherols and four tocotrienols occurring in nature all with vitamin
E activity. Of them, alpha-tocopherol has the highest vitamin E activity, which is determined by the
ability to overcome sterility in vitamin E-deficient rats. The biologic activity of vitamin E is expressed
as alpha-tocopherol equivalents, one alpha-tocopherol equivalent being the activity of 1 mg of natural
(RRR-) alpha-tocopherol. Chemically synthesized alpha-tocopherol contains eight different
stereoisomers, only one of which, RRR-alpha-tocopherol, occurs naturally. The biologic activity of the
synthetic stereoisomers varies, and 1 mg of synthetic D-l-alpha-tocopherol has 74% of the activity of
natural alpha-tocopherol (NRC, 1989). Additionally, the amount of vitamin E can be expressed in
international units (IU). One IU of vitamin E is equivalent to 1 mg of synthetic D-l-alpha-tocopheryl
acetate. In the literature, vitamin E is often used as a synonym for alpha-tocopherol, and in reference to
other studies, the term used there is also used here.
The most abundant tocopherol in our diet is alpha-tocopherol. The average daily intake of vitamin E in
Finland is 11 mg for men and 8 mg for women (National Public Health Institute, 1998). The main
sources are vegetable oils, wheat germ, green leafy vegetables, and nuts. The Institute of Medicine of
the National Academies has recently provided revised dietary recommendations for antioxidants. The
recommended daily intake of alpha-tocopherol is 15 mg for adults (Institute of Medicine, 2000). This
exceeds the former recommendation of 10 mg per day by the RDA in 1989 (NRC, 1989). Vitamin E
deficiency is rare in adults, associated with chronic fat malabsorption. Vitamin E is considered safe up
to 1 000 mg per day, however; vitamin E supplementation may be contraindicated in the presence of a
coagulation defect due to vitamin K deficiency or during anticoagulant therapy, as it reduces platelet
adherence and aggregation (Steiner, 1993; Mabile et al., 1999).
Vitamin E functions as an antioxidant, protecting cellular membranes from oxidative destruction.
Alpha-tocopherol inhibits free radical-induced lipid peroxidation and breaks the chain-reaction of
oxidation. During this action, alpha-tocopherol is oxidized to an alpha-tocopheroxyl radical, which can
be regenerated to alpha-tocopherol by vitamin C, glutathione, and coenzyme-Q (Kamal-Eldin and
Appelqvist, 1996; Wang and Quinn, 1999). Tocopherols act also as a singlet oxygen quencher (Kamal-
Eldin and Appelqvist, 1996). Beyond its antioxidant activity, alpha-tocopherol is suggested to inhibit
protein kinase C activity, which may be one mechanism through which alpha-tocopherol can inhibit
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smooth muscle-cell proliferation, and preserve nitric oxide-mediated arterial relaxation (Keaney Jr. et
al., 1999).
Beta-carotene
Carotenoids are naturally occurring pigments in green leafy vegetables and yellow fruits and
vegetables. Over 600 different carotenoids exist, and approximately 50 of them show vitamin A
activity (Bendich and Olson, 1989). Beta-carotene is one of them. One beta-carotene molecule is
enzymatically cleaved into two molecules of vitamin A - a fat-soluble vitamin - in the intestinal
mucosa. Not all dietary beta-carotene is converted to vitamin A; some is absorbed unchanged
(Thompson, JN et al., 1985). High doses of beta-carotene do not lead to high vitamin A levels, because
of a feedback mechanism. The bioavailability of beta-carotene appears to be better from supplements
than from vegetables (Brown et al., 1989). No actual recommendation for beta-carotene intake exists
other than equivalents used for recommendations for vitamin A intake: 900 retinol equivalents
(Sandström et al., 1996) or 1000 retinol equivalents (NRC, 1989), which correspond to 5.4 or 6 mg of
beta-carotene, respectively. Beta-carotene is considered an antioxidant. It is efficient singlet oxygen
quencher in vitro. It may be able to regenerate the alpha-tocopheroxyl radical into alpha-tocopherol
(Böhm et al., 1997). However, there is no convincing evidence that beta-carotene functions as an
antioxidant in vivo. That it functions, instead, as a pro-oxidant was suggested after the first controlled
trials indicated that beta-carotene supplementation increases risk for lung cancer among smokers (The
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994; Omenn et al., 1996).
Vitamin C
Vitamin C, ascorbic acid, is a water-soluble vitamin; deficiency in C leads to scurvy. The best sources
of vitamin C are citrus fruits, green vegetables, and berries. The average daily intake in Finland is 106
mg among men and 111 mg among women (National Public Health Institute, 1998). The recommended
dietary intake is 90 mg per day for men and 75 mg for women, and for smokers an additional 35 mg per
day (Institute of Medicine, 2000). Vitamin C is considered safe in doses 20-fold higher than the
average intake. Vitamin C acts as an antioxidant in biological fluids, scavenging reactive oxygen and
nitrogen species. It also regenerates other antioxidants: alpha-tocopherol, beta-carotene, urate, and
glutathione (Halliwell, 1996).
Several other dietary compounds also show antioxidant capacity, such as other carotenoids (lutein,
lycopene), flavonoids (polyphenolic substances) and the micronutrient selenium that forms an integral
part of the antioxidant enzyme glutathione peroxidase. The potential beneficial effect of these
substances on cardiovascular diseases (CVD) and cancer is under investigation in experimental and
epidemiological studies.
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2.4 Antioxidants and cardiovascular diseases
Ecological studies in western populations indicate that high consumption of vegetables and fruits, or
dietary antioxidant vitamins is related to lower cardiovascular mortality (Belizzi et al., 1994; Acheson
and Williams, 1983; Verlangieri et al., 1985; Ginter, 1979).
Serum and tissue levels of antioxidants
In a cross-cultural study, low serum alpha-tocopherol, vitamin C, and beta-carotene levels were
associated with higher mortality from CHD (Gey et al., 1991). However, another cross-cultural study
concluded that neither serum vitamin E nor C was associated with regional differences in CHD
mortality (Riemersma et al., 1989). In several case-control studies, low serum vitamin E levels have
been detected among patients with CHD (Sklodowska et al., 1991; Riemersma et al., 1991; Regnström
et al., 1996), whereas in three nested case-control studies, no association appeared (Hense et al., 1993;
Salonen et al., 1985; Kok et al., 1987). High serum beta-carotene levels have, in prospective studies,
been more consistently associated with lower risk for CHD (Street et al., 1994; Morris et al., 1994;
Greenberg et al., 1996). In a European multicenter case-control study, the association between adipose
tissue antioxidants and myocardial infarction was assessed. Alpha-carotene, beta-carotene, and
lycopene were all inversely associated with risk for myocardial infarction when examined separately,
but upon simultaneous analyses, only lycopene retained a significant association with risk for
myocardial infarction (Kohlmeier et al., 1997). Adipose tissue alpha-tocopherol was not associated
with risk for myocardial infarction (Kardinaal et al., 1993). Additionally, in a Dutch case-control study,
in which serum concentrations of carotenoids were compared between cases with aortic atherosclerosis
and healthy controls, serum lycopene showed an inverse association with aortic atherosclerosis among
non-smokers, whereas other carotenoids (alpha- and beta-carotene, lutein, zeaxanthin and beta-
cryptoxanthin) were not associated (Klipstein-Grobusch et al., 2000).
Prospective studies of antioxidant intake
Several large cohort studies have assessed associations between antioxidant intake and risk for CHD.
The largest cohort comprised over 87 000 middle-aged U.S. female nurses. That study showed an
inverse association between vitamin E intake and the risk for CHD, but this association was limited to
vitamin E-supplement users with a median intake of 208 IU/d (Stampfer et al., 1993). Correspondingly,
intake of vitamin E supplements was inversely associated with risk for CHD events or CHD mortality
in two other U.S. cohorts comprising either male health professionals or elderly men and women
(Rimm et al., 1993; Losonczy et al., 1996). Interestingly, dietary but not supplemental intake of vitamin
E showed a significant inverse association with risk for fatal CHD in a cohort of postmenopausal U.S.
women and among women and men in the Finnish Mobile Clinic cohort (Kushi et al., 1996; Knekt et
al., 1994). The Rotterdam Study and the Scottish Heart Health Study cohorts revealed no association
(Table 1) (Klipstein-Grobusch et al., 1999; Todd et al., 1999).
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Table 1. Association between vitamin E intake and risk for coronary heart disease (CHD) in
cohort studies.
Reference Population               Years of
                                 follow-up
RR (95% CI) for CHD
Stampfer et al., 1993 87 245 women
in USA
8 0.63 (0.45-0.88),
supplement users vs. nonusers
Rimm et al., 1993 39 910 men
in USA
4 0.64 (0.49-0.83),
419 vs. 6.4 mg*
Knekt et al., 1994 2 385 women
   &
2 748 men
in Finland
14 0.35 (0.14-0.88),
>7.1 vs. ≤5.3 mg*
0.68 (0.42-1.11),
>8.9 vs. ≤6.8 mg*
Kushi et al., 1996 34 486 women
in USA
7 0.38 (0.18-0.80),
≥9.6 vs. <4.9 mg*
Losonczy et al., 1996 11 178 women & men
in USA
10 0.59 (0.37-0.93),
supplement users vs. nonusers
Klipstein-Grobusch et
al., 1999
4 802 women & men
in Netherlands
4 1.07 (0.67-1.73),
>14.2 vs. 10.2 mg*
Todd et al., 1999 5 875 women
   &
5 754 men
in Scotland
10 1.17 (0.65-2.11),
>3.7 vs. 2.3 mg/4.18MJ*
0.95 (0.68-1.31),
>3.3 vs. 1.9 mg/4.18 MJ*
RR = relative risk
CI= confidence interval
*highest vs. lowest intake
High intake of beta-carotene was associated with decreased risk for CHD among men in the Scottish
Heart Health Study, but in the Health Professional Study and the Rotterdam Study the inverse
association was limited to smokers (Todd et al., 1999; Rimm et al., 1993; Klipstein-Grobusch et al.,
1999). In three other cohorts, no association occurred (Table 2)  (Kushi et al., 1996; Pandley et al.,
1995; Knekt et al., 1994).
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Table 2. Association between beta-carotene intake and risk for coronary heart disease (CHD) in
cohort studies.
Reference Population              Years of
                                follow-up
RR (95% CI) for CHD
Rimm et al., 1993 39 910 men
in USA
4 0.30 (0.11-0.82) for smokers
0.60 (0.38-0.94) for former smokers
≥14 388 vs. <5 030 IU*
Knekt et al., 1994 2 385 women
   &
2 748 men
in Finland
14 0.62 (0.30-1.29),
>383 vs. ≤182 ug*
1.02 (0.70-1.38),
>258 vs. ≤147 ug
Pandley et al., 1995 1 556 men
in USA
24 0.84, p for trend 0.09,
≥410 vs. ≤290 ug*
Kushi et al., 1996 34 486 women
in USA
7 1.19 (0.67-2.12)
≥13 027 vs. ≤4 349 IU*
Klipstein-Grobusch et
al., 1999
4 802 women & men
in Netherlands
4 0.55 (0.34-0.83) for current and
former smokers,
>1.57 vs. <1.1 mg energy-adjusted*
Todd et al, 1999 5 875 women
   &
5 754 men
in Scotland
10 0.75 (0.40-1.40),
>2705 vs. <978 ug / 4.18MJ*
0.68 (0.48-0.96),
>1 934 vs. <693 ug / 4.18MJ*
RR = relative risk
CI= confidence interval
*highest vs. lowest intake
High vitamin C intake was associated with decreased risk for CHD events or mortality among men in
the Scottish Heart Health Study and among both genders in the Epidemiologic Follow-up Study of the
National Health and Nutrition Examination Survey (NHANES) from the USA (Todd et al., 1999;
Enstrom et al., 1992). In the Western Electric Study cohort, an inverse association between vitamin C
intake and risk for CHD mortality was observed only among male nonsmokers (Pandley et al., 1995),
and in the Finnish Mobile Clinic cohort, the inverse association was limited to women (Table 3) (Knekt
et al., 1994).
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Table 3. Association between vitamin C intake and risk for coronary heart disease (CHD) in
cohort studies.
Reference Population               Years of
                                 follow-up
RR (95% CI) for CHD
Enstrom et al., 1992 6 869 women
   &
4 479 men
in USA
10 #0.75 (0.55-0.99)
#0.66 (0.53-0.82)
>50 mg+supplements vs. <49 mg*
Rimm et al., 1993 39 910 men
in USA
4 0.89 (0.68-1.16),
1 162 vs. 92 mg*
Knekt, et al., 1994 2 385 women
   &
2 748 men
in Finland
14 0.49 (0.24-0.98),
 >91 vs. ≤61 mg*
1.00 (0.68-1.45),
>85 vs. ≤60 mg*
Pandley et al., 1995 1 556 men
in USA
24 0.58, p for trend 0.04 for nonsmokers,
≥113 vs. ≤82 mg*
Kushi et al., 1996 34 486 women
in USA
7 1.43 (0.75-2.70),
≥196 vs. ≤87 mg*
Losconczy et al.,
1996
11 178 women & men
in USA
10 0.99 (0.75-1.33),
supplement users vs. nonusers
Klipstein-Grobusch et
al., 1999
4 802 women & men
in Netherlands
4 0.88 (0.56-1.38),
>126 vs. <87 mg*
Todd et al., 1999 5 875 women
   &
5754 men
in Scotland
10 0.63 (0.31-1.02),
>40 vs. <19 mg / 4.18MJ*
0.57 (0.40-0.83),
>29 vs. <16 mg / 4.18MJ*
#Standardized mortality ratio
RR = relative risk
CI= confidence interval
*highest vs. lowest intake
In conclusion, associations have been somewhat inconsistent, and in none of the studies did all three
antioxidants show any significant association. Different cohorts are not directly comparable because of
variation in study populations, in end-point definition, and in dietary methods. In cohorts, supplement
users may differ profoundly from those who do not voluntarily take supplements. They may be more
health-conscious, with a lower risk-factor profile. Most likely all factors associated with such behavior
are not measured and adjusted for in the analysis. Thus, the intake of antioxidant supplements may be a
surrogate for other factors associated with lower disease risk.
Trials of antioxidant supplementation
Up till now, several controlled trials of antioxidant supplementation have been conducted aimed at both
primary and secondary prevention of CVD. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study was a randomized, double-blind, placebo-controlled trial primarily designed to evaluate
preventive effects of alpha-tocopherol and beta-carotene supplementation on lung cancer and secondly
on other cancers and cardiovascular diseases among over 29 000 Finnish male smokers (The Alpha-
Tocopherol Beta Carotene Cancer Prevention Study Group, 1994). They were randomized to receive
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50 mg of alpha-tocopherol, or 20 mg of beta-carotene, or both, or placebo in one capsule per day.
Neither supplement affected significantly the incidence of angina pectoris, myocardial infarction or
CHD mortality during a median follow-up of 6 years (Virtamo et al., 1998; Rapola et al., 1996).
However, beta-carotene supplementation increased risk for fatal CHD (RR 1.43, 95% CI 1.08-1.88)
among men with previous myocardial infarction (Rapola et al., 1997). Risk for cerebral infarction was
significantly lower among men receiving alpha-tocopherol than among men not receiving it (RR 0.86,
95% CI 0.75-0.99), but risk for fatal subarachnoid hemorrhage was significantly higher among those
receiving alpha-tocopherol (RR 2.81, 95% CI 1.37-5.79) (Leppälä et al., 2000). Beta-carotene
supplementation was linked with higher risk for intracerebral hemorrhage (RR 1.62, 95% CI 1.10-2.36)
compared to risk in those receiving non (Leppälä et al., 2000).
In the Physicians' Health Study over 22 000 U.S. male physicians were randomized to receive 50 mg of
beta-carotene or placebo every other day for 12 years, with no effect observed on cardiovascular
mortality or myocardial infarction incidence (Hennekens et al., 1996). Similarly, no benefit of beta-
carotene was observed among nearly 40 000 U.S. women randomized to receive 50 mg of beta-
carotene, or 600 IU of alpha-tocopherol, or 100 mg of aspirin, or placebo every other day (Lee et al.,
1999). Because the beta-carotene part of this Women’s' Health Study was terminated after two years
the number of cardiovascular events was small. In these two studies only 13% and 11% of the
participants were smokers. In a fourth large trial, namely the Beta-Carotene and Retinol Efficacy Trial
(CARET), the effect of a combination of 30 mg of beta-carotene and 25 000 IU of vitamin A
supplementation on lung cancer and CVD diseases was assessed among 18 000 current or former
smokers or workers exposed to asbestos. A suggestion of increased risk for cardiovascular mortality
(RR 1.26, 95% CI 0.99-1.61) was observed among those who received beta-carotene and vitamin A
compared to risk in the placebo group during a mean follow-up of 4 years (Omenn et al., 1996).
The other trials were aimed at secondary prevention of cardiovascular diseases. The Heart Outcomes
Prevention Evaluation (HOPE) Study was a randomized trial testing ramipril and alpha-tocopherol (400
IU/d) among subjects who had experienced myocardial infarction or were otherwise at high risk for
cardiovascular events. Supplementation with alpha-tocopherol for 4.5 years showed no effect on
myocardial infarction, stroke or cardiovascular mortality (RR 1.05, 95% 0.90-1.22) among nearly 10
000 participants (The Heart Outcome Prevention Evaluation Study Investigators, 2000). In the
unblinded Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI)-
Prevenzione trial 11 000 patients with CHD were randomly assigned to receive 300 mg of alpha-
tocopherol or 1 g of fish-derived polyunsaturated fatty acids in a 2x2 factorial design. Alpha-tocopherol
supplementation showed no effect on secondary prevention of fatal or non-fatal cardiovascular events
(RR 0.98, 95% 0.87-1.10) during 3.5 years of follow-up (GISSI-Prevenzione Investigators, 1999).
Instead, among 2 002 patients with CHD in the Cambridge Heart Antioxidant Study (CHAOS)
supplementation with 400 IU and 800 IU of alpha-tocopherol reduced significantly the incidence of
non-fatal myocardial infarction (RR 0.23, 95% CI 0.11-0.47)  (Stephens et al., 1996). This surprisingly
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high risk-reduction was not, however, reflected in cardiovascular mortality (RR 1.18, 95% CI 0.62-
2.27). In this study, the median follow-up time was only 510 days, and the number of events was small.
The ongoing trials
Several trials are currently in progress, two of them aimed at primary and secondary prevention of
CVD among women (Rexrode et al., 2000; Manson et al., 1995). In the Women’s' Health Study, the
effect of 600 IU of alpha-tocopherol, or 100 mg of aspirin, or placebo every other day is being assessed
among nearly 40 000 postmenopausal female nurses. In the Women’s' Antioxidant and Cardiovascular
Study, the effect of 600 IU of alpha-tocopherol, or 500 mg of vitamin C, or 50 mg of beta-carotene, or
placebo on alternate days is being evaluated among 8 000 women with CVD in a 2x2x2-factorial
design. The Physicians’ Health Study is continuing with 7 500 voluntary former participants and 7 500
new physicians. The supplementation includes 50 mg of beta-carotene every other day, or 400 IU of
vitamin E every other day, or 500 mg of vitamin C daily, or multivitamin daily, or placebo in a
2x2x2x2 factorial design (Christen et al., 2000). In France, a primary prevention study
(Supplementation en Vitamines et Minéraux Antioxidants, SU.VI.M.AX) is being conducted among
the general population (over 12 000 men and women) with daily supplementation of combination of
vitamins (C and E and beta-carotene) and minerals (selenium and zinc) at nutritional doses testing their
effect on cancer and CVD mortality (Hercberg et al., 1998). In the U.K., the Heart Protection Study is
testing the effect of a combination of vitamins E (600 mg) and C (250 mg), and beta-carotene (20 mg)
daily on CHD among 20 000 patients with CVD or at high risk for it (Jha et al., 1995). In addition, in
autumn 2000, a new large-scale trial has begun in the USA, aimed primary at prevention of prostate
cancer and secondarily at prevention of other cancers and CHD with 400 mg of vitamin E and 200 µg
of selenium administered to over 30 000 men.
In summary, current evidence indicates that beta-carotene supplementation does not prevent CHD
events and may increase risk for fatal CHD, at least among smokers. Because the effect of alpha-
tocopherol supplementation on primary prevention of CVD has been assessed only in the ATBC Study,
one must wait for the ongoing trials to end before drawing conclusions. In considering vitamin E in
secondary prevention of CVD, the findings have been inconsistent. Hopefully, the ongoing trials will
clarify this matter. Vitamin C is under study; no data are yet available. Overall, the field is still open
and attracting the interest of many research groups.
2.5 Other nutrients and cardiovascular diseases
In addition to antioxidants, other nutrients have been studied in relation to CVD. The Seven Countries
Study showed that in populations with high intake of saturated fat and low intake of monounsaturated
fat, mortality for CVD was elevated (Keys et al., 1986). Two large U.S. cohorts showed similar
associations (Shekelle et al., 1981; Kushi et al., 1985). High intake of polyunsaturated fat has shown an
inverse association with risk for CHD in some cohorts such as the Nurses' Health Study and among the
control group of the Multiple Risk factor Intervention Trial (Hu et al., 1997; Dolecek, 1992). In
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contrast, in other cohort studies, no association has been evident (Kushi et al., 1985; Posner et al.,
1991; Ascherio et al., 1996). High intake of trans-fatty acids was associated with increased risk for
CHD in the Nurses’ Health Study and in the ATBC Study cohort (Willet et al., 1993; Pietinen et al.,
1997), but not in the Health Professionals cohort (Ascherio et al., 1996). Altogether, some
inconsistency in associations of different fatty acid groups and risk for CHD has been evident within
diverse cohorts (Posner et al., 1991; Ascherio et al., 1996; Hu et al., 1997; Pietinen et al., 1997). In
favor of current dietary recommendations that emphasize use of plant-derived food is the increasing
evidence of protective association between intake of fiber and risk for CHD (Kushi et al., 1985; Rimm
et al., 1996a; Pietinen et al., 1996; Todd et al., 1999; Wolk et al., 1999). However, such an association
has not been evident in all cohorts (Fehily et al., 1993; Kromhout et al., 1982). Furthermore, the
relation between alcohol consumption and risk for CHD has been extensively investigated in
observational studies. In a recent review by Rimm and his colleagues, a strong association between
moderate alcohol consumption and decreased risk for CHD was evident (Rimm et al., 1996b). The
authors concluded that the benefit is likely to derive from alcohol instead of other components of
different drink types.
2.6 Intermittent claudication
Etiology and prevalence
Atherosclerosis in the arteries of the lower extremities can result in insufficient blood flow during
exercise, leading to intermittent claudication, which is defined as pain in the calves induced on
exertion, which is relieved by short rest. Intermittent claudication is by definition a symptom. Thus its
diagnosis is subjective. Fluctuation of symptoms is typical. The degree of atherosclerotic stenosis in
pelvic and leg arteries correlates only partly with the severity of symptoms, because of differences in
collateral circulation. The prevalence of intermittent claudication among middle-aged or older men has
varied between 2.2% and 5.8% in Europe and the USA (Schroll and Munck, 1981; Criqui et al., 1985).
Risk factors for intermittent claudication
Intermittent claudication is more common among men than women and among individuals with other
manifestations of atherosclerosis (Reunanen et al., 1982; Criqui et al., 1992). The major risk factor is
smoking (Kannel and McGee, 1985; Ingolfsson et al., 1994; Bowlin et al., 1994). High serum total
cholesterol level, diabetes mellitus, and elevated blood pressure have been noted in cohort studies as
other risk factors (Kannel and McGee, 1985; Bainton et al., 1994; Dagenais et al., 1991). Higher
education was protective in one cohort, but not in another (Bowlin et al., 1994; Dagenais et al., 1991).
Relative weight has shown inconsistent associations with risk for intermittent claudication (Kannel and
McGee, 1985; Dagenais et al., 1991). Physical activity has not been assessed in these previous cohort
studies. The relation between diet and peripheral occlusive arterial disease has been assessed but not
extensively. In a cross-sectional study of 1 592 men and women from Edinburgh intake of fiber and
alcohol was positively associated with ankle brachial pressure index among men only, intake of alpha-
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tocopherol showed a similar positive association for both genders, and intake of vitamin C only among
nonsmokers (Donnan et al., 1993). In a hospital-based case-control study from Greece, high intake of
vitamin C, fiber, and polyunsaturated fatty acids suggested a protective association, whereas high
intake of saturated fatty acids, cholesterol, and protein increased risk for peripheral arterial occlusive
disease (Katsouyanni et al., 1991).
Vitamin E and intermittent claudication
Several decades ago, alpha-tocopherol supplementation was reported to relieve symptoms among
patients with angina pectoris and intermittent claudication (Shute et al., 1948). Since that observation,
several clinical studies with alpha-tocopherol supplementation have been performed, most of them,
although not all, suggesting an improvement in walking distance (Boyd et al., 1949; Ratcliffe, 1949;
Boyd and Marks, 1963; Haeger, 1982), (Hutchison and Williams, 1978) (Table 4). In two double-blind,
placebo-controlled studies, improvement in patients’ walking distance was noticeable among those
receiving alpha-tocopherol compared to results for those receiving placebo (Livingstone and Jones,
1958; Williams et al., 1962), but no such effect was evident in two other double-blind studies (Table 4)
(Hamilton et al., 1953; Westheim et al., 1975). Altogether, the body of evidence has been inconsistent,
and the opinion of the Cochrane Database is that not enough data exists to recommend treating
claudication patients with vitamin E supplements (Kleijnen and Mackerras, 1998). This year, new
evidence of the effect of alpha-tocopherol supplementation on the incidence of intermittent claudication
came from the HOPE Study. Alpha-tocopherol supplementation (400 IU/day) showed no preventive
effect (RR 1.02, 95% CI 0.92-1.13) among those who received alpha-tocopherol compared to placebo
during 4.5 years of follow-up (The Heart Outcome Prevention Evaluation Study Investigators, 2000).
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Table 4. Studies of alpha-tocopherol (AT) supplementation as treatment for intermittent claudication.
Reference Study type Dose of AT   No. of       Duration      Findings
per day         patients
Boyd et al.,
1949
Clinical 400 mg 81 Several
months
Subjective
improvement
Hutchison &
Williams, 1978
Clinical 1600 IU 9 5 years No effect on calf
blood flow
Ratcliffe, 1949 Controlled,
open,
nonrandomized
400 mg
other drugs
41
25
3 months Improvement in
walking test
Haeger, 1982 Controlled,
open,
nonrandomized
300 mg
other drugs
122
36
1-16 years Improvement in
walking test
Boyd and
Marks, 1963
Controlled,
single-blind,
Nonrandomized
400 mg
placebo
17
16
3 months Improvement in
walking test
Livingstone &
Jones, 1958
Controlled,
double-blind,
randomized
600 mg
placebo
20
20
10 months Improvement in
walking test
Hamilton, 1953 Controlled,
double-blind,
randomized
450 IU
placebo
20
21
3 months No difference in
walking test
between groups
Williams et al.,
1962
Controlled,
double-blind,
randomized
1600 mg
placebo
16
17
1 year Suggestion of
benefit in walking
test
Westheim et al.,
1975
Controlled,
double-blind,
randomized
300 mg
placebo
40
40
8 months No difference in
walking test
between groups
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2.7 Abdominal aortic aneurysm
Etiology and prevalence
Abdominal aortic aneurysm is a degenerative disorder of a multifactorial etiology. Atherosclerosis is
considered the major cause. Lately, more emphasis has been given to genetic and environmental factors
affecting the production and breakdown of elastin and collagen (Thompson, RW, 1996; Freestone et
al., 1995). The destruction of elastin unavoidably exposes collagen to a greater amount of
biomechanical stress, thus promoting the life-threatening event of rupture (Thompson, RW, 1996). In
patients with aneurysm, histological studies have shown atherosclerosis, inflammation, and loss of
elastin and collagen content in the aortic wall (Thompson, RW, 1996; Freestone et al., 1995). Based on
screening studies, the prevalence of abdominal aortic aneurysm has ranged from 4.1% to 8.5% among
men over 55 years old in Western populations (Simoni et al., 1995; Pleumeekers et al., 1995; Scott et
al., 1995). Male predominance has been observed, with a male/female ratio of 6 to 1 (Simoni et al.,
1995; Semmens et al., 1998).
Risk factors for abdominal aortic aneurysm
In the few prospective studies conducted, associations have been detected between abdominal aortic
aneurysm and smoking, hypertension, and elevated serum cholesterol level (Strachan, 1991; Reed et
al., 1992). Physical activity has shown an inverse association in one cohort but no association in
another, whereas height and relative weight were each associated with increased risk (Reed et al., 1992;
Hammond and Garfinkel, 1969). Data on diet and abdominal aortic aneurysm is almost absent. One
report comes from the Honolulu Heart Program cohort of 8 006 men of Japanese ancestry with 151
aneurysms during 20 years of follow-up. No association was observed between alcohol intake or
nutrients measured in a 24-hour dietary recall and the risk for aortic aneurysm (Reed et al., 1992).
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3. AIMS OF THE STUDY
The main aim of this work was to assess the relevance of antioxidants –both dietary and supplementary
- on peripheral atherosclerosis, i.e., intermittent claudication and abdominal aortic aneurysm.
The specific aims of is study were to assess:
1. The associations between diet, classical risk factors for atherosclerosis, concentrations of serum
alpha-tocopherol and beta-carotene and risk for intermittent claudication and abdominal aortic
aneurysm among male smokers. (I, IV)
2. The efficacy of alpha-tocopherol and beta-carotene supplementation on incidence of intermittent
claudication in a randomized double-blind placebo-controlled trial design among men free of this
symptom at study entry. (II)
3. Whether alpha-tocopherol and beta-carotene supplementation affect the recurrence of claudication
and risk for peripheral vascular surgery among subjects who reported intermittent claudication at
study entry. (III)
4. The effect of alpha-tocopherol and beta-carotene supplementation on the incidence of abdominal
aortic aneurysms that were either ruptured or electively operated on in a randomized double-blind
placebo-controlled trial design. (V)
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4. SUBJECTS AND METHODS
4.1 The ATBC Study
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study was a randomized, double-
blind, placebo-controlled trial. The primary aim was to test the effect of alpha-tocopherol and beta-
carotene supplementation on the incidence of lung cancer and secondly to evaluate its effect on other
cancers, all-cause mortality, and incidence of other diseases including atherosclerotic disorders. The
ATBC study was a joint project between the National Public Health Institute of Finland and the
National Cancer Institute of the USA.
Eligibility, recruitment, and exclusions
Participants were screened by a postal questionnaire from among a total population of 50- to 69-year-
old men living in 14 adjoining areas of southwestern Finland (n = 290 406). Men who were current
smokers (smoked five or more cigarettes per day) and willing to participate in the study (n = 42 957)
were invited to undergo baseline examinations. Exclusion criteria were previous malignancy other than
non-melanoma skin cancer, severe angina on exertion (Rose criteria, Grade 2) (Rose, 1962), chronic
renal insufficiency, cirrhosis of the liver, chronic alcoholism, anticoagulant therapy, current use of
supplements containing vitamin E (over 20 mg per day), beta-carotene (over 6 mg per day) or vitamin
A (over 20 000 IU per day), and other medical problems such as psychiatric disorders or physical
disability that might limit long-term participation. (Figure 1)
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Figure 1. Flow-chart of the ATBC Study
Source
population
290 406
Respondents
224 377
Deceased, or address
unknown, 7 050
Non-respondents, 58 979
Smokers willing
to participate
42 957
Excluded for medical reasons,
late refusals, non-smokers, users
of vitamin E or A or beta-
carotene, 13 711
Non-smokers, 170 206
Refusals, 11 214
Randomized
29 246
Late exclusions
113
ATBC Study
participants
29 133
Alpha-tocopherol
          7 286
Alpha-tocopherol
and beta-carotene
          7 278
Beta-carotene
7 282
Placebo
7 287
28
Baseline examinations
Before randomization, the men visited their local study center twice. They completed a questionnaire
covering their medical history, smoking habits, education and physical activity. Study nurses
interviewed the men with a structured questionnaire concerning intermittent claudication and angina
pectoris symptoms. Height, weight, and heart rate were measured. Blood pressure was measured by
mercury sphygmomanometry from the right arm while the subject was seated. The lower of two
measurements taken at least 1 minute apart was recorded. A blood sample was drawn and serum stored
at -70°C. The men were informed about the trial and signed the consent form. They received a diet-
history questionnaire to be completed at home. The questionnaire was checked at the second visit.
Randomization
 A total of 29 246 men were randomized into one of four intervention regimens. Randomization was
performed in blocks of eight, stratified by the 14 study areas. Randomization strata varied in size from
456 to 8 499 participants. Of the participants, 113 were subsequently found to be ineligible and were
excluded from the follow-up. Reasons for this were pre-existing malignancy, presence of undiagnosed
lung cancer at baseline, continued spontaneous use of vitamin supplements, and nonsmoker status.
These late-excluded participants were evenly distributed in the trial regimen groups: 24 in the alpha-
tocopherol group, 30 in the alpha-tocopherol and beta-carotene group, 28 in the beta-carotene group,
and 31 in the placebo group. Of these men, 98 were free of claudication at study entry. During follow-
up, ten of them developed intermittent claudication; three had been randomized to the alpha-tocopherol
group, two to the beta-carotene group, three to receive both supplements, and two to the placebo group.
Additionally, one of the late-excluded subjects underwent surgery for ruptured abdominal aortic
aneurysm. He had originally been randomized to the placebo group.
Intervention
Intervention regimens were 50 mg of alpha-tocopherol (synthetic dl-alpha-tocopheryl acetate, 50%
powder), 20 mg of beta-carotene (synthetic beta-carotene, 10% water-soluble beadlets), or both, or
placebo in one capsule per day. This design allowed investigation of two agents in a single trial setting,
provided there was no interaction between them. The four randomized groups were of equal size; 7 286
received alpha-tocopherol, 7 278 alpha-tocopherol and beta-carotene, 7 282 beta-carotene, and 7 287
placebo. Thus, according to the 2x2 design, about half received alpha-tocopherol (alpha-tocopherol
alone and alpha-tocopherol plus beta-carotene groups, n = 14 564) and the other half did not (beta-
carotene and placebo groups, n = 14 569); similarly, about half received beta-carotene (beta-carotene
alone and alpha-tocopherol plus beta-carotene groups, n = 14 560) and the other half did not (alpha-
tocopherol and placebo groups, n = 14 573). The study capsules were one-size hard gelatin capsules.
The formulations were colored with quinoline yellow. Capsules were provided in calendar blister
packs, each with a four-month supply.
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Time-table
Recruitment began in April 1985 and continued until June 1988. Active intervention continued until
April 30, 1993 and ranged from 5 to 8 years (median 6.1 years).
Capsule compliance and drop-outs
During follow-up visits, the capsule pack from the previous period was returned, residual capsules were
counted and recorded, and a new pack was dispensed. The overall capsule compliance was calculated
by dividing the number of capsules taken by the number of days in the trial. It was 93% with no
significant differences between the supplementation groups (range 93.1-93.4%). Only 4% were poor
compliers (i.e., took less than 50% of their capsules). Practically all poor compliers dropped out of the
study during their first trial year.
When a subject, for any reason, failed to attend further follow-up visits, he was considered a drop-out.
The overall drop-out rate during the trial varied only slightly across the four regimen groups (30.1% in
the alpha-tocopherol group, 31.0% in the alpha-tocopherol and beta-carotene group, 31.3% in the beta-
carotene group, and 30.7% in the placebo group). The most common reasons for dropping out were
illness (21%) and death (22%) (The ATBC Cancer Prevention Study Group, 1994).
Ethics and monitoring
The ATBC Study was approved by the institutional review boards of the National Public Health
Institute, Helsinki, Finland, and the National Cancer Institute, Bethesda, MD, USA. A four-member
Data and Safety Monitoring Committee was convened twice annually to review study progress and
scrutinize any side-effects and unexpected toxicity.
Laboratory measurements
Serum total and high-density lipoprotein (HDL) cholesterol concentrations were analyzed
enzymatically (CHOD-PAP method, Boehringer Mannheim) (Kattermann et al., 1984). HDL
cholesterol was measured after precipitation of low-density and very low-density cholesterol with
dextran sulphate and magnesium chloride (Kostner, 1976). Serum alpha-tocopherol and beta-carotene
concentrations were measured by high-performance liquid chromatography (Milne and Botnen, 1986).
Dietary assessment
The usual diet over the previous 12 months, including alcohol consumption, was assessed with a self-
administered diet-history questionnaire at baseline. This questionnaire covered the consumption of
about 200 food items and 70 mixed dishes. A picture booklet with 126 color photographs of foods,
each with 3 to 5 different portion sizes, helped the subjects to estimate average portions (Haapa et al.,
1985). The reproducibility and validity of this questionnaire has been assessed in a pilot study carried
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out among 190 men before the ATBC Study. The intraclass correlations for most nutrients ranged from
0.6 to 0.7, being highest for alcohol (0.88) in the reproducibility study (Pietinen et al., 1988). In the
validity study, Pearson correlation coefficients between nutrient intake values from food records and
food use questionnaires ranged from 0.40 for selenium to 0.80 for alcohol (Pietinen et al., 1988). Food
consumption and nutrient intakes were computed by use of the database of the National Public Health
Institute (Ovaskainen et al., 1996).
The follow-up
During the ATBC Study, participants visited their local study center every 4 months. They were asked
about their health (symptoms, visits to physicians), use of nontrial vitamin supplementation, and
smoking habits since their last visit. A subject was considered to have stopped smoking if he reported
not to have smoked at two consecutive follow-up visits (covering 8 months). During the study, 6 131
(21%) of the participants stopped smoking, with no differences across the supplementation groups.
Once a year, the questionnaire concerning cardiovascular symptoms was re-administered by interview.
Blood sampling was repeated for all participants in the third follow-up year. In addition to scheduled
study visits, the men were followed up by use of information in the Hospital Discharge Register and the
Register of Causes of Death.
 Serum alpha-tocopherol level increased by 50% among the supplemented subjects (baseline median
alpha-tocopherol 26.7 µmol/l vs. 40.3 µmol/l at 3 years with alpha-tocopherol supplementation),
whereas serum beta-carotene level increased 17-fold (baseline median beta-carotene 0.32 µmol/l vs.
5.51 µmol/l at 3 years with beta-carotene supplementation). Among nonsupplemented subjects, serum
levels of alpha-tocopherol and beta-carotene remained close to the baseline level (28.8 µmol/l for
alpha-tocopherol and 0.34 µmol/l for beta-carotene at 3 years).
Baseline characteristics
The median age of the participants was 57, they had smoked for 36 years, and they currently smoked
20 cigarettes per day. Their median blood pressure was 140/88 mmHg, and their median serum total
cholesterol concentration was 6.15 mmol/l, and HDL-cholesterol 1.12 mmol/l. Educational status was
low; 85% of the participants reported only elementary school as their basic education. Baseline
characteristics did not differ between the four treatment groups (Table 5).
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Table 5. Baseline characteristics (medians and proportions) of the ATBC Study participants by
supplementation group.
Baseline characteristics Alpha-
tocopherol
n = 7 286
Alpha-tocopherol
and beta-carotene
n = 7 278
Beta-
carotene
n = 7 282
Placebo
n = 7 287
Age, yr 57 57 57 57
Years of smoking 36 36 37 36
No. of cigarettes /day 20 20 20 20
Serum total cholesterol,
mmol/L
6.15 6.18 6.14 6.15
Serum HDL-cholesterol*,
mmol/L
1.11 1.11 1.12 1.12
Systolic blood pressure,
mmHg
140 140 140 140
Diastolic blood pressure,
mmHg
88 88 88 88
Body mass index, kg/m2 26 26 26 26
History of diabetes, % 4 5 5 4
Exercise in leisure-time#,
%
59 59 59 58
Education beyond
elementary school, %
15 16 15 15
*HDL = high-density cholesterol
#slight to moderate exercise
4.2 Subjects
Intermittent claudication (Studies I-III)
In order to study risk factors for intermittent claudication, and the effect of alpha-tocopherol and beta-
carotene supplementation on the incidence of claudication, 2 261 participants with history of
intermittent claudication at baseline were excluded (Study I and II) (Figure 2). Such a history of
intermittent claudication was based on an interview with questionnaire (Rose) concerning intermittent
claudication (n = 1 484) (Rose, 1962) or a self-reported history of claudication or arterial leg
obstruction diagnosed by a physician (n = 777). Median values for baseline characteristics among the
26 872 participants free of claudication at study entry are presented in Table 6. Median values were
similar in the four supplementation groups (II: Table 1, p. 3 477).
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Table 6. Baseline characteristics (medians, interquartile range, and proportions)
among subjects without intermittent claudication at study entry.
Characteristic Median
(interquartile range)
n=26 872
Age, yr 57 (53-61)
Years of smoking 36 (30-41)
No. of cigarettes / day 20 (15-25)
Serum total cholesterol, mmol/L 6.13 (5.43-6.92)
Serum HDL-cholesterol*, mmol/L 1.13 (0.96-1.34)
Systolic blood pressure, mmHg 140 (128-152)
Diastolic blood pressure, mmHg 88 (80-94)
Body mass index, kg/m2 26.0 (23.7-28.5)
Serum alpha-tocopherol, mg/L 11.5  (9.8-13.6)
Serum beta-carotene, µg/L 172 (110-262)
History of diabetes, % 4
Exercise in leisure-time#, % 59
Education beyond elementary school, % 16
Total energy intake, kcal/d 2733 (2269-3271)
Alcohol consumption, g/d 11.2 (2.6-25.7)
*HDL = high-density lipoprotein
#slight to moderate exercise
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Figure 2. Baseline data on intermittent claudication among ATBC Study participants.
ATBC participants
29 133
Free of intermittent
claudication at baseline
         26 872  Study I & II
Intermittent claudication at
baseline by Rose questionnaire
               1 484  Study III
Alpha-tocopherol
6 737
Alpha-tocopherol
and beta-carotene
6 689
Beta-carotene
6 702
Placebo
6 744
History of intermittent
claudication or arterial leg
obstrucion but no symptoms by
Rose questionnaire at baseline
777
Intermittent
claudication
during follow-up
683
Intermittent
claudication
during follow-up
650
Intermittent
claudication
during follow-up
632
Intermittent
claudication
during follow-up
613
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Study III assessed the effect of alpha-tocopherol and beta-carotene supplementation on recurrence of
claudication and on risk for peripheral vascular surgery. All participants who at baseline had been
detected by the Rose questionnaire as symptomatic (n = 1 484) were selected as subjects. Of these,
49% had severe and 51% mild typical intermittent claudication at study entry. They were evenly
distributed in the four supplementation groups (344 in the alpha-tocopherol, 390 in the alpha-
tocopherol and beta-carotene, 377 in the beta-carotene, and 373 in the placebo group). They were in
balance for all baseline factors (III: Table 1, p. 195).
Abdominal aortic aneurysm (Studies IV, V)
No selection was made among the ATBC Study participants for the analysis of abdominal aortic
aneurysm. All participants were followed through registers for rupture of an aneurysm or elective
surgery with graft placement (Study IV and V).
4.3 Endpoints
Intermittent claudication (Studies I-III)
Claudication was assessed by the Rose questionnaire, a structured questionnaire designed for
epidemiological field surveys (Rose, 1962). Typical intermittent claudication was defined as pain in
one or both calves induced on exertion and relieved at resting for ten minutes or less. This definition
includes both severe (pain occurs even while walking at an ordinary pace on the level) and mild (pain
occurs while walking uphill or hurrying) typical intermittent claudication. The questionnaire was re-
administered by interview once a year throughout the study. The first occurrence of typical intermittent
claudication was recorded as the end-point for Study I and for Study II.
In the analysis of the effect of antioxidant supplementation on the recurrence of intermittent
claudication (Study III), we used the annually reinterviewed questionnaires. In total, the subjects
reported 2 683 occurrences of typical claudication during 5 633 person-years. Information on
peripheral arterial surgery such as endarterectomy and any arterial bypass operation on the lower
extremities was collected from the National Hospital Discharge Register, which, in Finland, contains
records of all surgical operations. The first operation occurring during the trial was considered in the
analysis.
Abdominal aortic aneurysm (Studies IV, V)
The endpoint for studies concerning aortic aneurysm was based on two registers: the National Register
of Causes of Death, and the National Hospital Discharge Register. Both registers use the codes of the
International Classification of Diseases (ICD). We searched for ICD-8 codes 44100 to 44199 (used
until 1986), ICD-9 codes 4410A to 4419X (after 1986), and operation codes for aneurysmectomy with
graft placement. Altogether, we found 202 cases, of which 96 had one of these ICD codes for the cause
of death. We collected hospital and autopsy records to identify those with ruptured abdominal aortic
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aneurysm or nonruptured abdominal aortic aneurysm with prosthetic graft placement. Of the 202 cases,
181 fulfilled these criteria. Of the aneurysms, 77 were spontaneously ruptured and 104 did not rupture
but were operated upon either electively or urgently. The use of registers made it possible to obtain
information both from active participants and from dropouts.
4.4 Statistics
Cohort setting (Studies I and IV)
The association of risk factors with risk for intermittent claudication and abdominal aortic aneurysm
were analyzed by the Cox proportional hazards model (Breslow and Day, 1987). Risk factors were
divided into clinically relevant categories: age in 5-year age-groups; systolic and diastolic blood
pressure of ≤130, >130-160, >160, and ≤85, >85-100, >100 mmHg; serum total and HDL-cholesterol
of ≤5.0, >5.0-6.5, >6.5 and ≤0.9, >0.9-1.5, >1.5 mmol/L; body mass index (BMI) of ≤25, >25-27, >27
kg/m2; years of smoking numbering ≤32, >32-40, >40, and number of cigarettes smoked daily as ≤14,
15-24, >24. Three risk factors were dichotomous: leisure-time exercise (no exercise versus slight to
moderate exercise), education (elementary school versus junior high school or above) and history of
diabetes mellitus (yes, no). In the multivariate model, all these risk factors and alpha-tocopherol and
beta-carotene supplementation as main effects (alpha-tocopherol supplementation versus no alpha-
tocopherol supplementation and beta-carotene supplementation versus no beta-carotene
supplementation) were modelled simultaneously. Significance was tested by the likelihood ratio test in
Study I and by the Wald test in Study IV, where an ordinal variable with quartile scores was refitted
and its coefficient was tested. In Study I, cessation of smoking was used as a time-dependent variable
and was analyzed by the Cox proportional hazards model with simultaneous adjustment for the other
risk factors.
In the analysis of diet, all nutrient intakes except alcohol consumption were log-transformed and
energy-corrected by the residual method (Willet, 1990), and divided into quartiles, with the lowest
quartile as the reference group.  Alcohol intake was divided into five categories: nondrinkers, ≤15, >15-
30, >30-60, >60 g/day. The Cox proportional hazards model was used to estimate relative risks with
simultaneous adjustment for age, smoking, and energy intake. Each nutrient was added to the model
separately. In further analyses, the other risk factors were included in the model (for more details see
original publication I p. 894 and IV p. 6). Linearity of the trend was tested by the Wald test. For the
analyses of nutrients, 2 407 incident cases of claudication and 169 cases of abdominal aortic aneurysm
had completed the diet-history questionnaire at baseline.
In addition, associations between baseline serum alpha-tocopherol and beta-carotene concentrations
and risk for intermittent claudication and abdominal aortic aneurysm were assessed by the Cox
proportional hazards model. First, serum levels were adjusted for age, smoking, and total and HDL-
cholesterol, and second, a multivariate model was created including the other risk factors. Linearity of
the trend was tested by the Wald test.
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Trial setting (Studies II and V)
The incidence of intermittent claudication or abdominal aortic aneurysm was calculated by dividing
number of new events by cumulative person-years of follow-up. The Kaplan-Meier method was used
for calculation of cumulative incidence, and two-sided P-values derived from the unweighted log-rank
statistics were assessed for each of the four supplementation groups (Breslow and Day, 1987).
Incidences were also calculated for alpha-tocopherol compared to no alpha-tocopherol and for beta-
carotene compared to no beta-carotene, which allowed us to analyze the effects of alpha-tocopherol and
beta-carotene separately. All analyses were done according to the intention-to-treat principle. Cox
proportional hazards regression served for the crude and multivariate relative risk estimations, with
supplementation groups as explanatory variables. Baseline factors included in the multivariate models
were: age, smoking years, number of cigarettes per day, systolic and diastolic blood pressure, total and
HDL-cholesterol; and, additionally, in the analysis of claudication, also BMI, strenousness and
frequency of leisure-time exercise, alcohol consumption, and history of diabetes. The proportional
hazards assumption was tested and not rejected. Interaction between alpha-tocopherol and beta-
carotene, as well as between supplementations and baseline variables was tested by the likelihood ratio
test.
Treatment effect (Study III)
The effect of alpha-tocopherol and beta-carotene supplementation on recurrence of intermittent
claudication during follow-up was analyzed by the Generalized Estimating Equations (GEE model) for
dependent data, which takes into account the intraindividual correlation in repeated measurements of
claudication (Zeger and Liang, 1986). The analysis used the 2x2 - factorial design. Baseline variables
considered as risk factors for intermittent claudication were included in the model: age, years of
smoking, number of cigarettes smoked per day, BMI, consumption of alcohol, systolic and diastolic
blood pressure, total and HDL-cholesterol, and history of diabetes. Additionally we included in the
GEE-model cessation of smoking as a time-dependent variable. The effect of recurrence of intermittent
claudication on dropping out was modelled by the Poisson regression.
The effect of alpha-tocopherol and beta-carotene supplementation on risk for peripheral vascular
surgery was analyzed by the Cox proportional hazards model. All risk ratios reported were calculated
by stratified study area, due to possible areal variation in operation frequencies. Analysis of risk for
surgery was done according to the intention-to-treat principle.
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5. RESULTS
5.1 Intermittent claudication
Risk factors for intermittent claudication (Study I)
Classical risk factors
Risk for claudication increased with increasing age, number of cigarettes smoked per day, years of
smoking, systolic blood pressure, serum total cholesterol, and with baseline history of diabetes. Risk
was lower with high levels of serum HDL-cholesterol, education above elementary school, and more
leisure-time exercise. (Table 7)
Diet
Intake of energy was inversely associated with the risk for intermittent claudication. Of the
macronutrients, high energy-adjusted intakes of carbohydrate and fiber were significantly associated
with decreased risk for intermittent claudication. The energy-adjusted intakes of total fat and protein
showed no association with the risk for claudication, nor did alcohol consumption. (Table 8)
Of the different fatty-acid groups, energy-adjusted intake of polyunsaturated fatty acids showed a
significant inverse association with intermittent claudication in the age- and smoking-adjusted but not
in the multivariate model. Intake of n-6 polyunsaturated fatty acids was inversely associated with
claudication in both models (highest quartile vs. lowest, multivariate relative risk 0.91, 95% CI 0.81-
1.02; p for linear trend 0.048), whereas n-3 polyunsaturated fatty acids showed no association. Neither
dietary cholesterol, saturated fatty acids, nor cis- or trans-monounsaturated fatty acids showed any
effect on risk for claudication. (I: Table 2, p. 897)
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Table 7. Relative risks and 95% confidence intervals (CI) of life-style factors for
intermittent claudication among subjects without claudication at study entry.
Risk factor Cut-off points Multivariate relative risk*,
(95% CI)
P for
trend
Age, yr ≤55 1.00
>55-60 1.10 (0.99-1.24)
>60-65 1.32 (1.15-1.50)
>65 1.34 (1.14-1.57)
<0.01
Cigarettes /day ≤14 1.00
15-24 1.22 (1.09-1.36)
>24 1.36 (1.20-1.53)
<0.001
Years of smoking ≤32 1.00
>32-40 1.28 (1.15-1.42)
>40 1.57 (1.38-1.78)
<0.001
Body mass index, kg/m2 ≤25 1.00
>25-27 0.98 (0.88-1.09)
>27 0.98 (0.89-1.08) 0.9
Systolic BP#, mmHg ≤130 1.00
>130-160 1.24 (1.12-1.38)
>160 1.85 (1.61-2.13) <0.001
Diastolic BP, mmHg ≤85 1.00
>85-100 0.93 (0.85-1.02)
>100 0.88 (0.76-1.03) 0.2
Total cholesterol, mmol/L ≤5.0 1.00
>5.0-6.5 1.15 (1.01-1.31)
>6.5 1.33 (1.17-1.52) <0.001
HDL-cholesterol†, mmol/L ≤0.9 1.00
>0.9-1.5 0.75 (0.68-0.82)
>1.5 0.59 (0.51-0.69) <0.001
History of diabetes No 1.00
Yes 2.03 (1.75-2.35) <0.001
Education Elementary
school
1.00
Additional
education
0.60 (0.53-0.68) <0.001
Leisure-time exercise No 1.00
Yes 0.79 (0.73-0.85) <0.001
*Multivariate model with simultaneous adjustment for all the risk factors and, additionally, alpha-tocopherol and
beta-carotene supplementation group by Cox proportional hazards model
#BP = blood pressure
†HDL = high-density lipoprotein
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Table 8. Relative risks and 95% confidence intervals (CI) for intermittent claudication by quartiles of daily intake of
energy, macronutrients, and alcohol, among subjects without claudication at study entry.
Macronutrient Quartile
median
Relative risk, 95% CI
Age- and smoking-adjusted*
p for
trend†
Relative risk, 95% CI
Multivariate‡
p for
trend
Total energy, kcal 1987 1.00 1.00
2497 0.87  (0.78-0.97) 0.84  (0.74-0.96)
2967 0.92  (0.82-1.03) 0.85  (0.72-1.01)
3695 0.91  (0.81-1.02) 0.03 0.79  (0.61-1.02) 0.03
Fat, g 80 1.00 1.00
106 1.00  (0.89-1.13) 1.00  (0.89-1.13)
130 0.99  (0.88-1.11) 0.98  (0.87-1.10)
169 1.15  (1.03-1.28) 0.17 1.12  (1.00-1.25) 0.33
Protein, g 72 1.00 1.00
91 1.03  (0.92-1.15) 1.01  (0.91-1.14)
109 1.03  (0.92-1.15) 1.00  (0.89-1.12)
136 1.10  (0.98-1.23) 0.18 1.03  (0.92-1.16) 0.73
Carbohydrate, g 203 1.00 1.00
266 0.93  (0.83-1.04) 0.93  (0.83-1.04)
323 0.88  (0.78-0.98) 0.87 (0.78-0.98)
411 0.86  (0.77-0.97) 0.006 0.86 (0.76-0.96) 0.005
Fiber, g 15 1.00 1.00
21 0.86  (0.77-0.96) 0.84  (0.75-0.94)
27 0.88  (0.79-0.98) 0.87  (0.77-0.97)
37 0.91  (0.81-1.01) 0.01 0.87  (0.77-0.97) 0.002
Alcohol, g 0 1.00 1.00
5 0.96 (0.84-1.10) 1.02  (0.89-1.17)
23 1.01 (0.87-1.17) 1.10  (0.95-1.27)
40 0.93 (0.79-1.10) 1.01  (0.86-1.19)
78 0.96  (0.76-1.21) 0.59 1.08  (0.85-1.36) 0.48
All nutrients except alcohol were energy-corrected by the residual method for the analyses
Each nutrient was separately analyzed by the Cox model
*adjusted for baseline age, years of smoking, number of cigarettes smoked per day, and energy intake
†p for linear trend by Wald test
‡adjusted for baseline age, years of smoking, number of cigarettes smoked per day, energy intake, systolic blood
pressure, serum total and HDL-cholesterol, basic education, leisure-time exercise, history of diabetes, alpha-
tocopherol and beta-carotene supplementation, and smoking cessation
Intake of alcohol was divided into five categories: nondrinkers, ≤15, >15-30, >30-60, and >60 g/d
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High intake of carotenoids (sum of beta-carotene, alpha-carotene, gamma-carotene, lycopene,
capsanthin, cryptoxanthin, canthaxanthin, lutein and zeaxanthin) was significantly associated with
lower risk for claudication (highest quartile vs. lowest, multivariate relative risk 0.82, 95% CI 0.73-
0.92; p for linear trend < 0.001). Of the individual carotenoids, beta-carotene, lycopene, and lutein +
zeaxanthin showed a significantly lower risk for claudication with increasing levels of intake, whereas
intake of alpha-carotene showed no association. Intakes of vitamin E and its main constituents alpha-
tocopherol and gamma-tocopherol were significantly inversely associated with risk for claudication in
the age- and smoking-adjusted model, but after multivariate adjustment only gamma-tocopherol
maintained a significant association (highest quartile vs. lowest, relative risk 0.89, 95% CI 0.79-1.00; p
for linear trend 0.02). Intake of vitamin C showed a significant inverse association with risk for
claudication (highest quartile vs. lowest, multivariate relative risk 0.86, 95% CI 0.77-0.97; p for linear
trend 0.004). Dietary selenium was not associated with claudication. (I: Table 3, p. 898)
In further analysis, intakes of vitamin C and carotenoids were added to the multivariate model
simultaneously. Intake of carotenoids retained its significant inverse associations, but intake of vitamin
C was no longer associated with risk for claudication. Similarly, intakes of different carotenoids were
analyzed simultaneously in the multivariate model. Lycopene and lutein + zeaxanthin retained their
protective effect, whereas beta-carotene was not significantly associated with claudication. (I: p. 895)
Serum
Relative risk for claudication was significantly lower with higher levels of serum alpha-tocopherol or
beta-carotene (highest quartile vs. lowest, relative risk 0.88, 95% CI 0.77-1.00; p for linear trend 0.006,
and relative risk 0.77, 95% CI 0.68-0.86; p for linear trend <0.001, respectively) (I, Table 4, p. 899).
Correlations between serum and dietary alpha-tocopherol and beta-carotene were 0.21 and 0.23.
Effect of antioxidant supplementation on incidence of intermittent claudication (Study II)
Compliance and drop-out rate
Overall capsule compliance was 93% in all intervention groups. The overall drop-out rate was 30%,
similar in all intervention groups over time.
Effect of supplementation on intermittent claudication
During a mean follow-up of 4 years (107 370 person years), 2 578 new cases of typical intermittent
claudication were detected by the Rose questionnaire among the 26 872 men without claudication at
baseline. Incidence of intermittent claudication per 1 000 person-years was 22.7 in the placebo group,
25.4 in the alpha-tocopherol group, 24.3 in the alpha-tocopherol plus beta-carotene group, and 23.7 in
the beta-carotene alone group. The Kaplan-Meier curves of cumulative incidence are presented in
Figure 3. The overall difference between supplementation groups was not statistically significant (log-
rank test p = 0.13). An 11% increase in risk for developing intermittent claudication was observable
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among those who received alpha-tocopherol alone compared to those receiving placebo. Beta-carotene
supplementation or supplementation with both alpha-tocopherol and beta-carotene had no statistically
significant effect on incidence of claudication (Table 9). Interaction between alpha-tocopherol and
beta-carotene supplementation in the effect on intermittent claudication did not reach statistical
significance (p = 0.06).
A nonsignificant increase in risk for intermittent claudication occurred among those who received
alpha-tocopherol compared to those who did not (relative risk 1.07, 95% CI 0.99-1.15). Beta-carotene
supplementation showed no effect (relative risk 0.99, 95% CI 0.92-1.07 among those who received
beta-carotene compared to those not receiving it). Adjustment for baseline variables did not change
these results.
An interaction was found with one of the baseline variables – history of diabetes. Among those who
had diabetes at baseline, alpha-tocopherol supplementation significantly increased risk for claudication
compared to those not supplemented with alpha-tocopherol, whereas among those with no history of
diabetes, alpha-tocopherol supplementation did not affect risk for claudication. (II: p. 3477)
Table 9. Incidence and relative risk for intermittent claudication (IC) by supplementation group among subjects
without claudication at study entry.
Supplementation Number of
cases with IC
Incidence / 1000
person years
Crude relative risk,
95% CI*
Multivariate relative
risk†, 95% CI
Placebo 613 22.7 1.00 1.00
Alpha-tocopherol 683 25.4 1.11 (1.00-1.24) 1.11 (0.99-1.23)
Alpha-tocopherol
plus beta-carotene
650 24.3 1.06 (0.95-1.18) 1.04 (0.93-1.16)
Beta-carotene 632 23.7 1.04 (0.93-1.16) 1.01 (0.90-1.13)
Relative risks calculated by Cox proportional hazards model
*CI = confidence interval
†adjusted for baseline age, smoking years, daily number of cigarettes, serum total and HDL cholesterol,
systolic and diastolic blood pressure, BMI, alcohol consumption, physical activity, and history of diabetes
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Figure 3. Cumulative incidence of intermittent claudication in the four supplementation groups.
Treatment effect of antioxidant supplementation on intermittent claudication (Study III)
Compliance and drop-out rate
Overall capsule compliance was 91%. The drop-out rate was 44%, with deaths (n = 386) included. Risk
for dropping out was similar in all intervention groups, and recurrence of typical intermittent
claudication did not affect drop-out risk.
Recurrence of symptoms
At the annual interviews, the 1 484 men with claudication at baseline reported typical intermittent
claudication 2 683 times during 3.8 years of follow-up (5 444 person years). The average annual
prevalence of intermittent claudication was 48% throughout the study. The crude odds ratio for
recurrence of intermittent claudication by the GEE model was 0.97 (95% CI 0.81-1.15) among those
who received alpha-tocopherol compared to those who did not and 1.02 (95% CI 0.86-1.21) among
those who received beta-carotene compared to those who did not. Adjustment for baseline factors did
not change these results (III: Table 2, p. 196). The level of symptoms at baseline (severe or mild typical
symptoms) did not affect the results. No interaction was evident between alpha-tocopherol and beta-
carotene supplementation in their effects on claudication (p = 0.71).
Risk for surgery
Peripheral arterial surgery was performed on 101 (7%) subjects with claudication at baseline (23 in the
alpha-tocopherol group, 27 in the alpha-tocopherol plus beta-carotene group, 34 in the beta-carotene
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group, and 17 in the placebo group) during a mean follow-up time of 5.3 years (7 849 person years).
Relative risk for peripheral arterial surgery was 1.02 (95% CI 0.69-1.51) among those who received
alpha-tocopherol compared to risk of those who did not, and 1.51 (95% CI 1.01-2.26) among those who
received beta-carotene compared to those who did not. Adjustment for risk factors changed only
slightly these relative risks (Table 10). Among those who reported mild intermittent claudication at
baseline, beta-carotene supplementation significantly increased risk for surgery (odds ratio 2.44, 95%
CI 1.08-5.53) compared to risk of those not supplemented with beta-carotene. The corresponding risk
for surgery was only moderately increased (odds ratio 1.15, 95% CI 0.72-1.83) among those who
reported severe claudication at baseline. No interaction occurred between alpha-tocopherol and beta-
carotene supplementation in their effect on risk for surgery (p = 0.23).
Table 10. Relative risk and 95% confidence interval (CI) for peripheral arterial surgery by
supplementation with either alpha-tocopherol or beta-carotene among subjects with intermittent
claudication at study entry.
Supplementation Number of cases
with surgery
Crude relative risk,
95% CI
Adjusted* relative
risk, 95% CI
No alpha-tocopherol 51 1.00 1.00
Alpha-tocopherol 50 1.02 (0.69-1.51) 0.88 (0.58-1.33)
No beta-carotene 40 1.00 1.00
Beta-carotene 61 1.51 (1.01-2.26) 1.60 (1.05-2.44)
Relative risks calculated by Cox proportional hazards model and stratified by study area.
*Adjusted for baseline age, smoking years, daily number of cigarettes, serum total and HDL cholesterol,
systolic and diastolic blood pressure, BMI, alcohol consumption, and history of diabetes
Effect of smoking cessation
Incidence of intermittent claudication
The effect of smoking cessation on risk for claudication was assessed among men who were free of
claudication at study entry (n = 26 872). During follow-up, 4 538 (17% in all intervention groups)
subjects stopped smoking. Of these men, 271 reported claudication after smoking cessation during a
follow-up of 2.4 years. In a multivariate model (baseline variables and supplementation groups
included), smoking cessation reduced significantly the risk for claudication; the subsequent relative risk
was 0.86 (95% CI 0.75-0.99).
Recurrence of symptoms
Among the 1 484 men with intermittent claudication at study entry, as detected by the Rose
Questionnaire, 283 (19%) stopped smoking. Of these 66 were in the alpha-tocopherol group, 70 in the
alpha-tocopherol plus beta-carotene group, 76 in the beta-carotene group, and 71 in the placebo group.
Cessation of smoking decreased slightly but not significantly their subsequent risk for recurrence of
intermittent claudication (odds ratio 0.82, 95% CI 0.67-1.01).
44
5.2 Abdominal aortic aneurysm
Risk factors for abdominal aortic aneurysm (Study IV)
Classical risk factors
Risk for abdominal aortic aneurysm rose with increasing age, years of smoking, blood pressure, and
serum total cholesterol (Table 11). HDL-cholesterol showed a strong inverse association with risk. The
association was of similar magnitude whether HDL-cholesterol level was modelled alone, or along with
all other risk factors, including alcohol consumption.
Diet and serum
Intake of total energy was inversely associated with risk for abdominal aortic aneurysm (highest
quartile vs. lowest, relative risk 0.59, 95% CI 0.38-0.94; p for trend <0.01) (Table 12). The association
between energy intake and the risk for aortic aneurysm remained similar when energy derived from
alcohol was excluded. Neither energy-adjusted intake of macronutrients (fat, carbohydrate, protein, and
fiber) nor alcohol consumption was associated with risk (Table 12). When association of the different
fatty acid groups  (saturated, polyunsaturated, trans-, and cis- monounsaturated fatty acids) was
evaluated, there was no influence on risk. Additionally, analysis of dietary antioxidants (vitamin C and
E, carotenoids, and selenium) showed no association. Neither alpha-tocopherol nor beta-carotene
concentrations in serum were associated with risk for aortic aneurysm.
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Table 11. Relative risks and 95% confidence intervals (CI) of life-style factors for abdominal aortic
aneurysm among ATBC Study participants.
Risk factor Cut-off points Multivariate relative
risk*, (95% CI)
P for
trend
Age, yr ≤55 1.00
>55-60 1.81 (1.05-3.14)
>60-65 3.15 (1.76-5.65)
>65 4.60 (2.44-8.69) <0.001
Cigarettes /day ≤14 1.00
15-24 1.01 (0.70-1.46)
>24 0.81 (0.52-1.27) 0.32
Years of smoking ≤32 1.00
>32-40 1.45 (0.88-2.39)
>40 2.25 (1.33-3.81) <0.01
Body mass index, kg/m2 ≤25 1.00
>25-27 0.84 (0.57-1.26)
>27 0.78 (0.55-1.11) 0.13
Systolic BP†, mmHg ≤130 1.00
131-160 1.34 (0.87-2.07)
>160 1.95 (1.15-3.30) <0.05
Diastolic BP, mmHg ≤85 1.00
86-100 1.35 (0.93-1.94)
>100 1.78 (1.03-3.05) <0.05
Total cholesterol, mmol/L ≤5.0 1.00
>5.0-6.5 1.30 (0.77-2.20)
>6.5 1.81 (1.07-3.05) <0.01
HDL-cholesterol‡, mmol/L ≤0.9 1.00
>0.9-1.5 0.40 (0.29-0.56)
>1.5 0.15 (0.07-0.31) <0.001
History of diabetes No 1.00
Yes 0.43 (0.16-1.15) 0.09
Education Elementary
school
1.00
Additional
education
1.01 (0.67-1.54) 0.97
Leisure-time exercise Yes
No
1.00
1.29 (0.95-1.73) 0.10
*Multivariate model with simultaneous adjustment for all the risk factors and, additionally,
alpha-tocopherol and beta-carotene supplementation group by Cox proportional hazards
model.
† BP = blood pressure
‡HDL = high-density lipoprotein
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Table 12. Relative risks and 95% confidence intervals (CI) for abdominal aortic aneurysm by quartiles of daily intake of
energy, macronutrients, and alcohol among ATBC Study participants.
Macronutrient Quartile
median
Relative risk, 95% CI
Age- and smoking-adjusted*
P for
trend†
Relative risk, 95% CI
Multivariate‡
P for
trend
Total energy, kcal 1 984 1.00 1.00
2 495 0.87 (0.60-1.27) 0.92 (0.63-1.35)
2 969 0.60 (0.39-0.93) 0.63 (0.41-0.93)
3 695 0.56 (0.35-0.88) <0.01 0.59 (0.38-0.94) <0.01
Fat, g 80 1.00 1.00
106 1.08 (0.71-1.64) 1.14 (0.74-1.74)
130 0.89 (0.57-1.39) 0.92 (0.59-1.44)
169 0.91 (0.60-1.40) 0.51 0.95 (0.62-1.46) 0.60
Protein, g 72 1.00 1.00
91 0.86 (0.55-1.34) 0.82 (0.53-1.27)
109 0.91 (0.59-1.41) 0.87 (0.56-1.35)
136 1.26 (0.84-1.90) 0.25 1.13 (0.75-1.70) 0.51
Carbohydrate, g 203 1.00 1.00
266 0.73 (0.46-1.60) 0.71 (0.45-1.13)
322 0.84 (0.54-1.30) 0.78 (0.50-1.21)
411 1.14 (0.76-1.70) 0.39 1.02 (0.68-1.54) 0.76
Fiber, g 15 1.00 1.00
21 0.89 (0.58-1.36) 0.83 (0.54-1.27)
27 0.79 (0.51-1.23) 0.74 (0.48-1.15)
37 1.00 (0.66-1.51) 0.87 0.90 (0.59-1.36) 0.55
Alcohol, g 0 1.00 1.00
5 0.76 (0.50-1.16) 0.81 (0.53-1.24)
23 0.60 (0.35-1.01) 0.70 (0.41-1.19)
40 0.77 (0.44-1.36) 0.91 (0.51-1.63)
78 0.75 (0.31-1.83) 0.29 0.93 (0.38-2.29) 0.74
All nutrients except alcohol were energy-corrected by the residual method for the analyses
Each nutrient was separately analysed by the Cox model
*Adjusted for baseline age, years of smoking and total energy intake
†P for linear trend by Wald test
‡Adjusted for age, years of smoking, total energy intake, serum total and HDL-cholesterol, systolic and
diastolic blood pressure, and alpha-tocopherol and beta-carotene supplementation group.
Intake of alcohol divided into five categories: nondrinkers, ≤15, >15-30, >30-60, and >60 g/d
Effect of antioxidant supplementation on incidence of abdominal aortic aneurysm (Study V)
Effect of supplementation
During a mean follow-up of 5.8 years (169 408 person years) 181 cases of abdominal aortic aneurysm
were detected. The incidence of abdominal aortic aneurysm per 10 000 person years was 10.6 for
alpha-tocopherol supplementation, 8.6 for alpha-tocopherol plus beta-carotene supplementation, 11.8
for beta-carotene supplementation, and 11.5 for placebo (Table 13). No differences between the
intervention groups were statistically significant (Figure 4). Crude relative risks for abdominal aortic
aneurysm compared to placebo were 0.92 (95% CI 0.61-1.38) for those who received alpha-tocopherol,
0.76 (95% CI 0.50-1.15) for those who received alpha-tocopherol plus beta-carotene, and 1.03 (95% CI
0.69-1.52) for those who received beta-carotene. Adjustment for the baseline variables affected these
results only slightly (Table 13). There was no interaction between alpha-tocopherol and beta-carotene
supplementations (p = 0.06). None of the baseline variables modified the effect of supplements on the
incidence of aortic aneurysm. The crude relative risk for aortic aneurysm was 0.83 (95% CI 0.62-1.11)
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among those who received alpha-tocopherol compared to those who did not, and 0.93 (95% CI 0.69-
1.24) among those who received beta-carotene compared to those who did not (V: Table 2, p. 16).
Table 13. Incidence and relative risk for abdominal aortic aneurysm by supplementation group among
ATBC Study participants.
Supplementation Number of cases
with aneurysm
Incidence / 10 000
person-years
Crude relative risk,
(95% CI)*
Multivariate relative
risk†, (95% CI)
Placebo 49 11.5 1.00 1.00
Alpha-tocopherol 45 10.6 0.92 (0.61-1.38) 0.87 (0.58-1.31)
Alpha-tocopherol
plus beta-carotene
37 8.6 0.76 (0.50-1.16) 0.75 (0.49-1.16)
Beta-carotene 50 11.8 1.03 (0.69-1.52) 0.99 (0.66-1.47)
Relative risks calculated by Cox proportional hazards model
*CI = confidence interval
†adjusted for age, years of smoking, number of daily cigarettes, serum total and HDL-cholesterol,
systolic and diastolic blood pressure
Figure 4. Cumulative incidence of large abdominal aortic aneurysm in the four supplementation groups.
Aneurysms were divided into two subgroups: nonruptured and ruptured. Risk for nonruptured
abdominal aortic aneurysm tended to be 30% lower among those who received alpha-tocopherol than
among those who did not. This difference did not, however, reach statistical significance. Beta-carotene
supplementation showed no effect. There was no difference in relative risk for ruptured aortic
aneurysm among those who received alpha-tocopherol and those who did not, or among those who
received beta-carotene and those who did not. (V: Table 3, p. 17)
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6. DISCUSSION
6.1 Methodological considerations
The ATBC Study
The ATBC Study was primarily aimed at evaluating the effect of alpha-tocopherol and beta-carotene
supplementation on lung cancer incidence. However, the secondary aim was to evaluate the effect of
antioxidants on the development of other cancers and cardiovascular diseases. The study protocol
included at baseline structured questionnaires concerning intermittent claudication and angina pectoris
in addition to questions on medical history. Several measurements were performed to assess risk
factors for atherosclerosis. During follow-up, structured questionnaires were re-administered, current
health was evaluated, and diagnoses of illnesses were obtained through the National Hospital Discharge
and Mortality Registers.
Subjects
All subjects were men with a long smoking history, since the primary interest was in preventing lung
cancer. They were, however, at high risk for cardiovascular diseases as well, because smoking is one of
the major risk factors for atherosclerosis. Strictly, findings of he present study can be generalized only
to male smokers. Because all subjects were of late middle-age, it is obvious that to some extent
atherosclerotic changes were already present at baseline. During enrollment some selection occurred
due to previous and current diseases, and due to impaired ability to participate in a long-term study.
This should be kept in mind when interpreting the results, because it is generally hypothesized that
subjects who are not reachable or are considered ineligible for follow-up studies, are at the highest risk
for disease.
Validity of definition of intermittent claudication
The definition of intermittent claudication was based on the Rose questionnaire. In the original study
by Rose, the sensitivity and specificity of this questionnaire were reported to be high, 92% and 100%,
respectively, based on 37 patients with intermittent claudication and 18 patients with other leg pain
(Rose, 1962). In a larger sample of 586 claudicants and 61 patients with other leg pain, sensitivity was
60% and specificity 91% (Leng and Fowkes, 1992). It is likely that misclassification has led to a slight
underestimation of the effect of supplementation (Fleiss, 1973). There is, however, no reason to assume
that such misclassification would vary by supplementation group. In the cohort analyses,
misclassification may have attenuated the associations between risk factors and endpoint. In assessment
of intermittent claudication, it should be kept in mind that by definition claudication is a symptom. It
reflects peripheral atherosclerosis, but the severity of atherosclerotic lesions may vary between
individuals. Fluctuation of symptoms and spontaneous recovery are typical for intermittent
claudication; this variability in its natural course partly explains the modest constancy of questionnaire
responses (48%).
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Compliance and drop-out
The overall capsule compliance in the ATBC Study was high. Compliance was assessed by calculating
the number of capsules used per days in the trial. The rise in serum alpha-tocopherol and beta-carotene
levels measured in the third follow-up year confirms the good compliance. One obvious problem in the
analysis of intermittent claudication is the lack of information from dropouts. It was possible to detect
cases only among active participants. Whether incidence of intermittent claudication would differ
among dropouts and those who participated, was impossible to assess. No significant differences
existed in dropout incidences from the four intervention groups; neither did occurrence of intermittent
claudication significantly modify dropout incidence. Respectively, in the cohort setting, endpoint
information was lost due to dropping out. Risk factors may have affected not only risk for intermittent
claudication but also risk for dropping out. How the lack of endpoint data of dropouts affected the
observed risk estimates was impossible to ascertain.
Validity of register-based endpoints
Two endpoints in this work were based on registers: surgery on arteries of the lower extremities and
abdominal aortic aneurysm. Operation codes for arterial bypass or endarterectomy came from the
Hospital Discharge Register, and register data was used as such. In a Finnish evaluation, codes for any
operation from the Hospital Discharge Register matched hospital records in 85% of cases (Aro et al.,
1990). Based on such results, register data seem to be sufficiently valid for analysis. Hospital and
autopsy records of aortic aneurysms were collected and diagnoses checked. The number of ATBC
Study subjects with asymptomatic and uncomplicated abdominal aortic aneurysm is unknown.
However, because the aneurysm endpoint comprised ruptured aneurysms and those electively operated
on, one can expect to have identified most subjects with large, clinically relevant abdominal aortic
aneurysms. Sudden-death cases that were not autopsied must be considered potentially a group of
missing cases, although autopsies were performed on 64% of the ATBC Study participants who had
CVD as their underlying cause of death.
Validity of the dietary questionnaire
The dietary questionnaire used in the ATBC Study was validated and its reproducibility and validity
were found to be satisfactory (Pietinen et al., 1988). Pearson correlation coefficients between food
records and food-use questionnaires were 0.69 for vitamin C, 0.70 for vitamin E, and 0.73 for fiber.
Dietary assessment always involves some degree of measurement error, and misclassification leads to
attenuation of associations. Over-reporting of healthy foods and under-reporting of unhealthy ones is
one problem. Energy adjustment, as introduced by Willett, corrects some of this problem in reporting
(Willett, 1990).
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6.2 Risk factors
Classical risk factors
Risk factors under study may be divided into those affected by lifestyle (smoking, exercise, diet) and
those that cannot (age). However, many of the risk factors for atherosclerosis are combinations; diet
and genome both affect serum cholesterol level, with much variation between individuals. In this work,
several risk factors commonly referred to as classical risk factors for atherosclerotic diseases were
clearly associated with risk for both intermittent claudication and large abdominal aortic aneurysms.
Increasing age, elevated blood pressure, high serum total cholesterol concentration, and long history of
smoking were significant risk factors. Similar associations have been observed in prospective studies of
risk factors for intermittent claudication (Kannel and McGee, 1985; Bainton et al., 1994; Dagenais et
al., 1991) and abdominal aortic aneurysm (Strachan, 1991; Reed et al., 1992). That high serum HDL-
cholesterol showed a strong inverse association with intermittent claudication and especially with
abdominal aortic aneurysm adds to the increasing amount of evidence of the importance of HDL-
cholesterol as a protective factor. Other mechanisms of HDL beyond reverse cholesterol transport have
been suggested, such as its antioxidative effect (Francis and Perry, 1999). Although all subjects were
long-term smokers, cessation of smoking was beneficial. It lowered risk for subsequent claudication
among those free of this symptom at study entry and suggested a benefit for those subjects with
claudication at baseline. These findings place further emphasis on preventive work in modifying the
lipid profile and encouraging nonsmoking to improve public health.
High intake of energy showed a protective association with risk for claudication and aortic aneurysm,
though it is unlikely that energy intake itself is a protective factor. Need for energy depends on level of
daily exercise, body mass, and individual metabolism. A high amount of exercise is associated with an
increased need for energy; thus energy intake can be interpreted as a crude measure of physical activity,
especially after controlling for BMI, age, and sex (Willett and Stampfer, 1998). In this study, leisure-
time exercise was inversely associated with risk only for claudication. Measurement of exercise
through one question in a questionnaire naturally limits validity, and may attenuate the possibility of
detecting true differences in the level of daily exercise. On the other hand, a strong protective
association between HDL-cholesterol level and both end-points gives further support for this
explanation, since regular exercise is reported to increase HDL-cholesterol concentration (Sagiv and
Goldbourt, 1994).
Diet
Diet may be considered healthy or unhealthy. Several countries have offered recommendations on how
people should construct their diets. Generally, vegetable oils, vegetables, and fruits are favored, with
advice to reduce intake of animal fat and meat. In the present work, the associations observed between
nutrient intake and risk for claudication are in agreement with the general consensus as to a healthy
diet. High intake of fiber, carbohydrates, n-6 polyunsaturated fatty acids, and antioxidant vitamins was
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inversely associated with risk for intermittent claudication. However, none of the nutrients were
associated with risk for large abdominal aortic aneurysm. This may indicate that, in the pathogenesis of
aneurysm formation, genetic factors and the toxic effect of smoking play a greater role than do dietary
factors.
Serum
Findings for serum alpha-tocopherol and beta-carotene levels were coherent with dietary findings. High
levels of cholesterol-adjusted serum alpha-tocopherol and beta-carotene were associated with low risk
for intermittent claudication, but not for abdominal aortic aneurysm. Serum alpha-tocopherol and beta-
carotene correlated with dietary intake, although the correlation coefficient was quite weak. In
prospective studies, inverse associations between serum antioxidant levels and cardiovascular disease
risk have been more consistent for beta-carotene (Greenberg et al., 1996) than for alpha-tocopherol
(Salonen et al., 1985), although neither has shown an association in all studies (Sahyoun et al., 1996).
6.3 Supplementation
Prevention
Neither alpha-tocopherol nor beta-carotene supplementation showed any preventive effect on incidence
of intermittent claudication or large abdominal aortic aneurysm. An unexpected subgroup result
appeared. Among subjects with a history of diabetes mellitus, the incidence of intermittent claudication
was higher in those on alpha-tocopherol supplementation compared to no alpha-tocopherol
supplementation. No plausible hypothesis exists through which alpha-tocopherol supplementation
could enhance development of claudication among subjects with diabetes. This observation thus may
be a chance finding resulting from multiple comparisons.
These findings of no benefit are not surprising, since the first trials of primary prevention of
cardiovascular diseases with antioxidant supplements have not revealed such favorable effects as were
expected based on the observational studies (Stampfer et al., 1993; Rimm et al., 1993; Klipstein-
Grobusch et al., 1999; Todd et al., 1999). In the ATBC Study, no preventive effect on coronary heart
disease was evident with either antioxidant (Virtamo et al., 1998; Rapola et al., 1996), whereas risk for
cerebral infarction was significantly reduced with alpha-tocopherol supplementation (Leppälä et al.,
2000). The effect of alpha-tocopherol supplementation on mortality of cerebral infarction did not reach
statistical significance. However, risk for fatal subarachnoid hemorrhage was significantly increased
with alpha-tocopherol supplementation (Leppälä et al., 2000). In two other large-scale trials, no benefit
was observed from beta-carotene supplementation against cardiovascular diseases or mortality (Omenn
et al., 1996; Hennekens et al., 1996). In addition, no effect of alpha-tocopherol supplementation on
claudication incidence was evident among subjects at high risk for cardiovascular disease in the HOPE
Study (The Heart Outcome Prevention Evaluation Study Investigators, 2000). Neither was there any
effect on secondary prevention of coronary heart disease with alpha-tocopherol supplementation in the
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HOPE and the GISSI-Prevenzione studies (The Heart Outcome Prevention Evaluation Study
Investigators, 2000; GISSI-Prevenzione Investigators, 1999). In contrast, in the CHAOS trial the risk
for non-fatal myocardial infarction was significantly reduced among CHD patients who received alpha-
tocopherol, however, a nonsignificant 30% increase in CHD mortality occurred during supplementation
lasting less than one and a half years (Stephens et al., 1996).
This work seems to include a discrepancy between findings of a relation between dietary and
supplemented antioxidants and incidence of claudication. Several explanations can be given. The
antioxidant hypothesis may hold at physiological concentrations of antioxidants but not at
pharmacological ones. Thus, supplementation with high doses would not be beneficial to a well-
nourished population. Second, the duration of supplementation may have been too short or occurred at
a too-advanced age. However, because atherogenesis is a continuous process,  antioxidant
supplementation would be expected to be beneficial at any time. Dietary intake, on the other hand, is
suggested to reflect life-long exposure. Third, high intakes of specific antioxidants are markers of high
consumption of vegetables and fruits. These contain many additional compounds – both known and
unknown – that may be responsible for the beneficial association detected in epidemiological studies.
Finally, these nutritional factors may, merely be indicators of a more healthy life-style.
Treatment effect
For decades patients with intermittent claudication have been treated with vitamin E supplements. The
early studies were mainly clinical observations, and the subsequent few controlled, double-blind studies
were of small size and with a short duration of supplementation (Livingstone and Jones, 1958;
Williams et al., 1962; Hamilton et al., 1953). Indeed, the Cochrane database, in which current evidence
is reviewed, gives no recommendation for treatment of intermittent claudication with alpha-tocopherol
(Kleijnen and Mackerras, 1998). In the present work, neither alpha-tocopherol nor beta-carotene
supplementation showed any effect on recurrence of symptoms among subjects with intermittent
claudication. Instead, beta-carotene significantly increased risk for vascular surgery among those
subjects with mild typical intermittent claudication at study entry. The mechanism behind this finding
is unclear. Some evidence exists that beta-carotene is incorporated into atherosclerotic plaques (Prince
et al., 1988). Whether beta-carotene may favor smooth, developing plaques that are prone to rupture
instead of being incorporated into calcified plaques can only be hypothesized. It is thus concluded that
alpha-tocopherol supplementation did not relieve intermittent claudication, and beta-carotene
supplementation even appeared harmful.
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7. CONCLUSIONS
1. A diet rich in antioxidants, carbohydrate, fiber, and polyunsaturated fatty acids was associated with
decreased risk for intermittent claudication; additionally, physical activity, amount of education, and
smoking cessation showed a protective association. Nutrient intake had no association with risk for
abdominal aortic aneurysm. However, the classic risk factors for atherosclerotic diseases were
associated both with the risk for intermittent claudication and for abdominal aortic aneurysm.
2. Alpha-tocopherol or beta-carotene supplementation in doses several-fold higher than the average
dietary intake showed no preventive effect on incidence of intermittent claudication.
3. Alpha-tocopherol supplementation did not affect recurrence of claudication or risk for surgery
among subjects with claudication at study entry. Beta-carotene supplementation increased slightly the
risk for vascular surgery, but showed no effect on the recurrence of symptoms.
4. Long-term supplementation with alpha-tocopherol or beta-carotene showed no effect on risk for
large abdominal aortic aneurysm.
Thus, among long-term male smokers, supplemental antioxidants seem to have no beneficial effect on
intermittent claudication or abdominal aortic aneurysm. Instead, a lifestyle aiming at non-smoking,
improving the lipid profile, lowering blood pressure, and increasing physical activity seems to offer
advantages against development both of intermittent claudication and of abdominal aortic aneurysm.
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9. APPENDICES
The Rose questionnaire (Rose, 1962).
